UnionClin has recently signed a Master Service Agreement (MSA) with MEDSIR, a leading oncology-focused CRO headquartered in Spain. The two companies have established a strategic partnership and launched full collaboration in international multi-center clinical development services.

As the Spring Equinox marks the start of a new year, 2025 witnessed a quiet yet pivotal shift in China’s innovative pharmaceutical sector. With the industry’s hype fading, the focus has converged on a core question: how to generate denser, more reliable clinical evidence – a priority that outweighs chasing fleeting technological trends.

From “Single Service” to “Ecosystem Co-construction”: Wang Junlin on How UnionClin Empowers the Globalization of China’s Innovative Drugs

On May 29th, the fifth UnionClin Salon closed-door event, co-hosted by the Department of Medical Oncology, Fudan University Shanghai Cancer Center and Shanghai UnionClin Co., Ltd (UnionClin), successfully concluded. This salon brought together influential clinical researchers, pharmaceutical company leaders, industry strategy experts, and investors, focusing on the pain points of new neoplasm drug research and development (R&D). Attendees directly confronted core industry contradictions and engaged in intense intellectual discussions.